抗菌药物对大肠杆菌防突变浓度研究

Mutant Prevention Concentration of Antibacterial Drugs against E.coli

通过测定临床常用抗菌药物对大肠杆菌的防突变浓度(MPC)、耐药突变选择窗(MSW)、及耐药选择性指数(SI),为临床治疗提供抗菌药物用药参考,以降低细菌耐药情况的发生.方法:采用琼脂稀释法分别测定利福平、头孢羟氨苄、头孢地尼对大肠杆菌ATCC25922的MPC及SI.结果:利福平对大肠杆菌的MPC,MSW及SI分别为32μg/mL、12～32μg/mL、2.67;头孢羟氨苄的MPC,MSW及SI分别为30μg/mL、17～30μg/mL、1.76;头孢地尼的MPC、MSW及SI分别为0.5μg/mL、0.28～0.5μg/mL、1.78;结论:头孢地尼的抑菌效果明显高于其余两种药物,且其在较低浓度水平即可抑制耐药菌株的产生、防止耐药情况出现.

Objective Mutant prevention concentration （MPC）, mutant selection window（MSW） and drug selective index （SI） of the clinical commonly with antibiotics on E. coli were used to provide reference for clinic treatment and reduce the anti- biotic resistance of bacteria. Method：Detection of MPC, MSW and SI of Rifampiein, Cefadroxil and Cefdinir on E. coli was performed through agar dilution method. Results： MPC, MSW and SI of Rifampicin on E. coli were ： 32μg/mL, 12--32μg/ mL,2.67 respectively; MPC, MSW and SI of Cefadroxil： 30μg/mL,17--30μg/mL,1.76 respectively; MPC, MSW and SI of Cefdinir： 0.5μg/ml, 0. 28--0. 5μg/mL, 1.78 separately. Conclusion： Cefdinir could inhibit bacteria better than the other two drugs, and at relatively low concentration levelsit can inhibit drug-resistant strains and prevent the emergence of drug resist- ance.